CLPT: EPS of ($0.2) missed estimates of ($0.174) and sales of $7.77M missed estimates of $8.23M. Sales grew 31%, driven by higher demand for disposables and new product offerings. Its margins increased from last year, and the growth outlook is strong for its biologics and drug delivery markets.
ODD: EPS of $0.2 beat estimates of $0.11 and sales of $124M beat estimates of $119.03M. Sales growth was strong, with 27% growth on the year, and with a 23.3% adjusted EBITDA margin. It generated strong free cash flow and repurchased $100M worth of shares in the quarter.
OLY: Reported net earnings of $2.92M and sales of $102.92M. Its service revenue declined 1% mostly due to lower trading profits, but total sales grew 3% due to an increase in trust income.